A chiropractic session gets funny when Anna McNulty’s incredible flexibility becomes part of every adjustment. The pretend specialist talks about different areas of her back while casually bending her ...

The label expansion builds on Inluriyo’s existing monotherapy indication, approved about a year ago. (Angus Liu/Fierce Pharma) Eli Lilly is sharpening its competitive edge in the crowded oral SERD ...

Lilly still boasts a robust pipeline of next-gen obesity candidates, led by retatrutide. (iStock / Getty Images Plus) Eli Lilly has put the kibosh on an early-stage obesity drug after the candidate ...

Eli Lilly & Co. has been laying the groundwork for a broader move into women’s health, assembling experts and hunting for new medicines across conditions including bone health and endometriosis, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Eli Lilly remains on a shopping spree, agreeing to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences in a deal that bolsters the drugmaker’s immunology portfolio. Eli Lilly ...

Eli ⁠Lilly said on Monday it would acquire privately held Merida Biosciences for up to $2.88 billion in cash, strengthening its immunology portfolio with an experimental treatment for thyroid-related ...

Eli Lilly is suing six entities that it alleges are selling black market versions of its experimental weight-loss drug retatrutide. Lilly’s lawsuits target U.S. entities selling illegal retatrutide ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Eli Lilly, the American drug giant, had another record-breaking quarter. The weight-loss injection Zepbound saw sales soar 46% in the second quarter to $4.9 billion. The FactSet consensus was for $4.7 ...